From a therapeutic perspective, targeting HDAC3— particularly in combination with ferroptosis inducers such as RSL3 or Erastin – could offer a selective strategy to eradicate treatment-resistant CRC cells. Here, HDAC3 is linked to colorectal carcinoma.